• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda covered exercise/tax liability with 9,096 units of Ordinary Shares, decreasing direct ownership by 3% to 317,822 units (SEC Form 4)

    8/22/25 6:01:59 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TBPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Farnum Rhonda

    (Last) (First) (Middle)
    C/O THERAVANCE BIOPHARMA US, LLC
    901 GATEWAY BLVD

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Theravance Biopharma, Inc. [ TBPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, COMM & MEDICAL AFFAIRS
    3. Date of Earliest Transaction (Month/Day/Year)
    08/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 08/20/2025 F 9,096(1) D $13.39 317,822 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
    /s/ Brett A. Grimaud, Attorney-in-Fact 08/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TBPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TBPH

    DatePrice TargetRatingAnalyst
    9/12/2025$28.00Buy
    B. Riley Securities
    8/6/2024$15.00 → $10.00Outperform → Market Perform
    Leerink Partners
    4/12/2024$21.00Buy
    BTIG Research
    1/8/2024Outperform → In-line
    Evercore ISI
    5/23/2022$12.00Outperform
    SVB Leerink
    3/2/2022$10.00 → $11.00Underweight
    Morgan Stanley
    2/24/2022$8.00 → $12.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $12.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $TBPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Theravance Biopharma with a new price target

    B. Riley Securities initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $28.00

    9/12/25 7:53:21 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously

    8/6/24 8:00:45 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Theravance Biopharma with a new price target

    BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00

    4/12/24 7:40:50 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

    DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of

    11/20/25 11:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma to Participate in Upcoming Investor Conferences

    DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Evercore Healthcare ConferenceLocation: Coral Gables, FLFormat: Fireside ChatDate: Thursday, December 4, 2025Time: 8:20-8:40 AM ETWebcast Oppenheimer Movers in Rare Disease SummitLocation: New York, NYFormat: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving CatalystsDate: Thursday, December 11, 2025Time: 2:15-2:45 PM ET Therav

    11/19/25 6:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitabilityOpen-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025TRELEGY year-to-date sales on track to achieve $50 million milestone in 20252Strong balance sheet with $333 million in cash and no debtDUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the thi

    11/10/25 4:05:00 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    SEC Filings

    View All

    SEC Form 10-Q filed by Theravance Biopharma Inc.

    10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)

    11/12/25 4:16:06 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Theravance Biopharma Inc.

    144 - Theravance Biopharma, Inc. (0001583107) (Subject)

    11/12/25 9:02:50 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Theravance Biopharma, Inc. (0001583107) (Filer)

    11/10/25 4:11:07 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Winningham Rick E gifted 9,900 units of Ordinary Shares, received a gift of 9,900 units of Ordinary Shares and covered exercise/tax liability with 56,817 units of Ordinary Shares, decreasing direct ownership by 4% to 1,651,069 units (SEC Form 4)

    4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

    11/21/25 7:10:33 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Broshy Eran sold $809,250 worth of Ordinary Shares (45,000 units at $17.98), decreasing direct ownership by 34% to 60,204 units (SEC Form 4)

    4/A - Theravance Biopharma, Inc. (0001583107) (Issuer)

    11/14/25 6:00:16 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Broshy Eran sold $1,068,250 worth of Ordinary Shares (59,000 units at $18.11), decreasing direct ownership by 49% to 46,204 units (SEC Form 4)

    4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

    11/13/25 9:00:16 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Samaha Eli bought $7,798,440 worth of COM (999,800 units at $7.80) (SEC Form 4)

    4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

    8/9/24 6:02:35 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Samaha Eli bought $13,117,335 worth of COM (1,499,124 units at $8.75) (SEC Form 4)

    4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

    5/3/24 4:19:22 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Financials

    Live finance-specific insights

    View All

    Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

    DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of

    11/20/25 11:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitabilityOpen-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025TRELEGY year-to-date sales on track to achieve $50 million milestone in 20252Strong balance sheet with $333 million in cash and no debtDUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the thi

    11/10/25 4:05:00 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

    Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous SystemTopline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater Beach, FL. The Company will have one platform presentation and three poster presentations on its clinical development program for ampreloxetine, a potential first-

    10/29/25 6:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Leadership Updates

    Live Leadership Updates

    View All

    Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

    Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a

    12/21/23 5:00:00 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors

    Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire

    4/12/23 7:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors

    DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si

    4/11/23 4:05:00 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

    SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)

    11/14/24 9:53:41 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

    SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)

    11/12/24 5:53:05 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

    SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)

    11/4/24 3:33:04 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care